Last August, after Merck & Co. Inc. disclosed positive but not especially compelling results with its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, Credit Suisse analyst Vamil Divan concluded that the company made the right decision to quit, although drugs in the class "may still have a role in patients with certain genetic predispositions."